4.McHutchinson J and Sulkowski M. Scientific Rationale and study design of the individualised dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis. doi:10.1111/j.1365-2893.2008.00973.x
5.Schering-Plough Reports Top-Line Results of the IDEAL Study. Schering-Plough News Release, 2008. (Accessed April 16, 2008, at http://www.schering-plough.com/schering_plough/news/release.....)
Contact: Mike Nelson, Roche, +41(79)572-5165, Michelle Marchione, Axon Communications, +44 (0) 208 439 9449
